Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS
Inhalt archiviert am 2024-05-07

Development of ultrasensitive diagnostic assays for the detection of genetic disorders, infections and for monitoring the therapeutic success following gene therapy

CORDIS bietet Links zu öffentlichen Ergebnissen und Veröffentlichungen von HORIZONT-Projekten.

Links zu Ergebnissen und Veröffentlichungen von RP7-Projekten sowie Links zu einigen Typen spezifischer Ergebnisse wie Datensätzen und Software werden dynamisch von OpenAIRE abgerufen.

Verwertbare Ergebnisse

At present, the most widely employed diagnostic methodologies are based on antibody detection (RIA and ELISA). In addition to the problems associated with radioactive materials these methods generally suffer from low specificity and sensitivity. Furthermore, they do not offer quantification. In recent years, nucleic acid (DNA and RNA) based systems employing PCR technology have been developed. Although these assays might be more sensitive than ELISA systems, the applications still suffer from draw backs such as i) high cost, ii) time consumption, iii) lack of flexibility, iv) lack of standardization, and v) lack of automation.The proposed assay system is innovative because it is based on a different concept in comparison to similar technologies. This is achieved partly by the implementation of fluorochrome labelled primers. Thereby, the sensitivity is markedly improved approaching quantitation of absolute numbers of copies in the samples. In addition, the system offers flexibility and the potential of automation. The assay is characterized by real-time monitoring and on line detection showing an extremely low detection limit of 10-100 initial DNA copies. A considerable advantage is that the core technology on the one side is based on fluorescence energy transfer (FRET) which is shareware, whereas on the other side the PCR technology is patented by Hoffmann La Roche. In addition, the assays are adapted to targets representing marked diseases for which the group of RTD partners has access to patient materials.The diagnostic tool to be developed offers excellent advantages and benefits over existing systems, as being i) low-priced, ii) fast, iii) easy to use, iv) offering quick adaptation to gene mutations, and v) employing a core technology which can be used unrestricted.

Suche nach OpenAIRE-Daten ...

Bei der Suche nach OpenAIRE-Daten ist ein Fehler aufgetreten

Es liegen keine Ergebnisse vor

Mein Booklet 0 0